Abstract
Cognitive dysfunction has been described as a hallmark feature of schizophrenia since the first descriptions of the illness. Kraepelin described a number of features of the disorder that he thought reflected impairments in cognition and attention. He also speculated that cognitive impairments were mediated by neurobiologic dysfunction, specifically impairments in the functions of the frontal lobe. Since Kraepelin’s time, there have been many changes in the general conceptions of schizophrenia, including ideas regarding the status and importance of cognitive impairment in the illness. Due to increased sophistication of neuropsychologic assessment and neuroimaging techniques, cognitive impairment has again has risen to the forefront of importance in terms of theories regarding the etiology and treatment of schizophrenia.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Kraepelin E: Dementia Praecox and Paraphrenia. Edinburgh: Livingstone; 1919.
Palmer BW, Heaton RK, Paulsen JS, et al.: Is it possible to be schizophrenic yet neuropsychologically normal? Neuropsychology 1997, 11:437–446.
Hyde TM, Nawroz S, Goldberg TE, et al.: Is there cognitive decline in schizophrenia? A cross-sectional study. Br J Psychiatry 1994, 164:494–500.
Rund BR: A review of longitudinal studies of cognitive functions in schizophrenia patients. Schizophr Bull 1998, 24:425–435.
Harvey PD, Silverman JM, Mohs RC, et al.: Cognitive decline in late-life schizophrenia: a longitudinal study of geriatric chronically hospitalized patients. Biol Psychiatry 1999, 45:32–40.
Harvey PD, Parrella M, White L, et al.: The convergence of cognitive and adaptive decline in late-life schizophrenia. Schizophr Res 1999, 35:77–84.
Amminger GP, Schlogelhofer M, Lehner T, et al.: Premorbid performance IQ deficit in schizophrenia. Acta Psychiatr Scand 2000, 102:414–422.
Cannon TD, Bearden CE, Hollister JM, et al.: Childhood cognitive functioning in schizophrenia patients and their unaffected siblings: a prospective cohort study. Schizophr Bull 2000, 26:379–393. This study assesses the course of and the degree to which cognitive deficits in childhood predict schizophrenia. The results suggest that premorbid cognitive dysfunction of schizophrenia is a relatively stable indicator of vulnerability.
Bilder RM, Goldman RS, Robinson D: Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry 2000, 157:549–559.
Riley EM, McGovern D, Mockler D, et al.: Neuropsychological functioning in first-episode psychosis: evidence of specific deficits. Schizophr Res 2000, 43:47–55.
Mojtabai R, Bromet EJ, Harvey PD, et al.: Neuropsychological differences between first-admission schizophrenia and psychotic affective disorders. Am J Psychiatry 2000, 157:1453–1460.
Weickert TW, Goldberg TE, Gold JM, et al.: Cognitive impairments in patients with schizophrenia displaying preserved and compromised intellect. Arch Gen Psychiatry 2000, 57:907–913. Given the inconsistencies in the literature, this work helps to elucidate the course and pattern of neurocognitive deficits in schizophrenia. The results suggested a modal decline in IQ from estimated premorbid levels. However, the results also suggest that intellectual decline is not a universal characteristic of schizophrenia. Furthermore, deficits in executive function and attention were found in schizophrenic patients with average premorbid intellectual levels and no evidence of IQ decline, indicating that these deficits may be core features of schizophrenia independent of the variability of IQ impairment among patients.
Rabinowitz J, Reichenberg A, Weiser M, et al.: Cognitive and behavioural functioning in men with schizophrenia both before and shortly after first admission to hospital: crosssectional analysis. Br J Psychiatry 2000, 177:26–32.
Fucetola R, Seidman LJ, Kremen WS, et al.: Age and neuropsychologic function in schizophrenia: a decline in executive abilities beyond that observed in healthy volunteers. Biol Psychiatry 2000, 48:137–146.
Granholm E, Morris S, Asarnow RF, et al.: Accelerated age-related decline in processing resources in schizophrenia: evidence from pupillary responses recorded during the span of apprehension task. J Int Neuropsychol Soc 2000, 6:30–43.
Eyler Zorrilla LT, Heaton RK, McAdams LA, et al.: Crosssectional study of older outpatients with schizophrenia and healthy comparison subjects: no differences in age-related cognitive decline. Am J Psychiatry 2000, 157:1324–1326.
Heaton RK, Gladsjo JA, Palmer BW, et al.: Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry 2001, 58:24–32.
Green MF: What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996, 153:321–330.
Green MF, Kern RS, Braff D, et al.: Neurocognition and functional outcome in schizophrenia: are we measuring the right stuff? Schizophr Bull 2000, 26:119–136.
Addington J, Addington D: Neurocognitive and social functioning in schizophrenia: a 2.5 year follow-up study. Schizophr Res 2000, 44:47–56.
Velligan DI, Bow-Thomas CC, Mahurin RK, et al.: Do specific neurocognitive deficits predict specific domains of community function in schizophrenia? J Nerv Ment Dis 2000, 188:518–524. This work contributes to our understanding of which specific neurocognitive deficits predict community outcome. By understanding which neurocognitive functions determine specific domains of adaptive functioning compensatory strategies may be developed to improve community outcome. The results indicate that verbal memory predicts all measures of community outcome, vigilance predicts social outcome and executive functioning predicts work and activities of daily living.
McGurk SR, Moriarty PJ, Harvey PD, et al.: Relationship of cognitive functioning, adaptive life skills, and negative symptom severity in poor-outcome geriatric schizophrenia patients. J Neuropsychiatry Clin Neurosci 2000, 12:257–264.
Schretlen D, Jayaram G, Maki P, et al.: Demographic, clinical, and neurocognitive correlates of everyday functional impairment in severe mental illness. J Abnorm Psychol 2000, 109:134–138.
Harvey PD, McGurk SR: Cost of schizophrenia: focus on vocational impairment. The Economics of Neuroscience 2000, 2:42–48.
Rupp A, Keith SJ: The cost of schizophrenia. Psychiatr Clin North Am 1993, 16:413–423.
Sevy S, Davidson M: The cost of cognitive impairment in schizophrenia. Schizophr Res 1995, 17:1–3.
McGurk SR, Meltzer HY: The role of cognition in vocational functioning in schizophrenia. Schizophr Res 2000, 45:175–184.
Suslow T, Schonauer K, Ohrmann P, et al.: Prediction of work performance by clinical symptoms and cognitive skills in schizophrenic outpatients. J Nerv Ment Dis 2000, 188:116–118.
Medalia A, Dorn H, Watras-Gans S: Treating problem-solving deficits on an acute care psychiatric inpatient unit. Psychiatry Res 2000, 97:79–88.
Velligan DI, Bow-Thomas CC, Huntzinger C, et al.: Randomized controlled trial of the use of compensatory strategies to enhance adaptive functioning in outpatients with schizophrenia. Am J Psychiatry 2000, 157:1317–1323. This work provides new information on the effect of novel cognitive adaptation training techniques on the cognitive functions of schizophrenics. These compensatory strategies were found to significantly improve global functioning and psychotic symptoms and to significantly reduce relapse of schizophrenic patients rates over a 9-month follow-up.
Hegarty JD, Baldessarini RJ, Tohen M: One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry 1994, 151:1409–1416.
Davidson M, Keefe RSE: Cognitive impairment as a target for pharmacological treatment in schizophrenia. Schizophr Res 1995, 17:123–129.
Keefe RSE, Perkins S, Silva SM, et al.: The effect of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999, 25:201–222.
Harvey PD, Keefe RSE: Studies of cognitive change with novel antipsychotic treatment in schizophrenia. Am J Psychiatry 2001, 158:176–184. This meta-analytic review of the treatment effects of atypical antipsychotic medications on the cognitive functions of schizophrenic patients highlights the methodological limitations in previous studies and therefore is helpful in the design of future studies. In addition, this review suggests that specific aspects of cognitive functioning are more improved than others by atypical antipsychotics. Finally, this review points out that the improvement in cognition with atypical antipsychotics is moderate at best.
Purdon SE, Jones BD, Stip E, et al.: Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol: the Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry 2000, 57:249–258. One of the first studies to directly compare the atypical antipsychotic medications on their cognitive effects in schizophrenic patients. While the results suggested some superior cognitive benefits of olanzapine relative to risperidone, this study was very limited by a small sample size and high rates of attrition.
Harvey PD, Moriarty PJ, Serper MR, et al.: Practice-related improvement in information processing with novel antipsychotic treatment. Schizophr Res 2000, 46:139–148.
Liu SK, Chen WJ, Chang CJ, et al.: Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: A trial of risperidone versus haloperidol. Neuropsychopharmacology 2000, 22:311–319.
Allen DN, Goldstein G, Forman SD, et al.: Neurologic examination abnormalities in schizophrenia with and without a history of alcoholism. Neuropsychiatry Neuropsychol Behav Neurol 2000, 13:184–187. Despite the understanding that schizophrenic patients have a high rate of co-morbid substance abuse disorders, little is known about the adverse effects of these substances on neurologic and neuropsychological functions of schizophrenic patients. The results of this study suggest that schizophrenic patients with a history of alcoholism have greater overall neurologic impairment, particularly in the area of perceptual functions.
Serper MR, Bergman A, Copersino ML: Learning and memory impairment in cocaine-dependent and comorbid schizophrenic patients. Psychiatry Res 2000, 93:21–32.
Serper MR, Copersino ML, Richarme D: Neurocognitive functioning in recently abstinent, cocaine-abusing schizophrenic patients. J Subst Abuse 2000, 11:205–213.
Brebion G, Amador X, David A, et al.: Positive symptomatology and source-monitoring failure in schizophrenia: an analysis of symptom-specific effects. Psychiatry Res 2000, 95:119–131.
Bocker KB, Hijman R, Kahn RS, et al.: Perception, mental imagery and reality discrimination in hallucinating and non-hallucinating schizophrenic patients. Br J Clin Psychol 2000, 39:397–406.
O’Leary DS, Flaum M, Kesler ML, et al.: Cognitive correlates of the negative, disorganized, and psychotic symptom dimensions of schizophrenia. J Neuropsychiatry Clin Neurosci 2000, 12:4–15. This study increases our knowledge of the relationship between specific cognitive abnormalities and clinical symptoms of schizophrenia. The results indicate that negative symptoms are related to impaired verbal learning and memory, verbal fluency and visual memory while disorganized symptoms are related to lower verbal IQ and poor concept attainment.
Brebion G, Amador X, Smith M, et al.: Depression, psychomotor retardation, negative symptoms, and memory in schizophrenia. Neuropsychiatry Neuropsychol Behav Neurol 2000, 13:177–183.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Harvey, P.D., Bowie, C.R. & Friedman, J.I. Cognition in schizophrenia. Curr Psychiatry Rep 3, 423–428 (2001). https://doi.org/10.1007/s11920-996-0038-7
Issue Date:
DOI: https://doi.org/10.1007/s11920-996-0038-7